Did Surgery Partners’ Weaker Guidance and Legal Probe Just Shift Surgery Partners’ (SGRY) Investment Narrative?

Simply Wall St.12-06

In November 2025, Surgery Partners, Inc. cut its full-year revenue and adjusted EBITDA guidance, citing delays in capital deployment and earnings lost from ambulatory surgical center divestitures, and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589281938?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","is_english":true,"pubTime":"2025-12-06 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589281938","market":"nz","top_or_hot":-1,"title":"Did Surgery Partners’ Weaker Guidance and Legal Probe Just Shift Surgery Partners’ (SGRY) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>In November 2025, Surgery Partners, Inc. cut its full-year revenue and adjusted EBITDA guidance, citing delays in capital deployment and earnings lost from ambulatory surgical center divestitures, and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/did-surgery-partners-weaker-guidance-and-legal-probe-just-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Surgery Partners’ Weaker Guidance and Legal Probe Just Shift Surgery Partners’ (SGRY) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Surgery Partners’ Weaker Guidance and Legal Probe Just Shift Surgery Partners’ (SGRY) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-06 17:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/did-surgery-partners-weaker-guidance-and-legal-probe-just-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In November 2025, Surgery Partners, Inc. cut its full-year revenue and adjusted EBITDA guidance, citing delays in capital deployment and earnings lost from ambulatory surgical center divestitures, and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/did-surgery-partners-weaker-guidance-and-legal-probe-just-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGRY","symbol_name":"Surgery Partners, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/did-surgery-partners-weaker-guidance-and-legal-probe-just-sh","article_id":"2589281938","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/did-surgery-partners-weaker-guidance-and-legal-probe-just-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589281938","pubTimestamp":1765012701,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In November 2025, Surgery Partners, Inc. cut its full-year revenue and adjusted EBITDA guidance, citing delays in capital deployment and earnings lost from ambulatory surgical center divestitures, and now faces a federal securities law investigation by Levi & Korsinsky.\nThis combination of weaker guidance and legal scrutiny raises fresh questions about the reliability of prior assumptions on growth, capital allocation, and portfolio optimization.\nWe’ll now examine how the reduced guidance...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGRY":"Surgery Partners, Inc.","BK4185":"保健护理机构"},"translate_title":"Surgery Partners较弱的指导和法律调查是否只是改变了Surgery Partners(SGRY)的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGRY":1.5},"content_text":"In November 2025, Surgery Partners, Inc. cut its full-year revenue and adjusted EBITDA guidance, citing delays in capital deployment and earnings lost from ambulatory surgical center divestitures, and now faces a federal securities law investigation by Levi & Korsinsky. This combination of weaker guidance and legal scrutiny raises fresh questions about the reliability of prior assumptions on growth, capital allocation, and portfolio optimization. We’ll now examine how the reduced guidance and related investigation could influence Surgery Partners’ previously optimistic investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward.AdvertisementSurgery Partners Investment Narrative RecapTo own Surgery Partners, you need to believe that outpatient surgical volumes and higher acuity procedures will keep shifting into its centers, supporting better profitability over time. The guidance cut and resulting investigation appear to directly challenge the near term acquisition and portfolio optimization story, which has been a key catalyst, while also adding to existing concerns around execution risk and capital deployment. The recent appointment of Justin Oppenheimer as Chief Operating Officer and National Group President, effective January 1, 2026, stands out against this backdrop. His operating background in complex orthopedic care could matter for how effectively Surgery Partners converts its pipeline of higher acuity procedures into sustainable margin improvement, particularly if the company must lean more on organic performance while capital deployment remains under scrutiny. Yet investors should be aware that, if acquisition timing continues to slip and portfolio changes remain disruptive, the combination of weaker guidance and higher legal risk could... Read the full narrative on Surgery Partners (it's free!)Surgery Partners' narrative projects $4.3 billion revenue and $164.3 million earnings by 2028.Uncover how Surgery Partners' forecasts yield a $25.73 fair value, a 50% upside to its current price.Exploring Other PerspectivesSGRY Earnings & Revenue Growth as at Dec 2025 Two different fair value estimates from the Simply Wall St Community span from US$25.73 to US$69.88, underscoring how far apart individual views can be. You should weigh this wide spread against the recent guidance cut and investigation risk, and consider how both might affect Surgery Partners’ ability to convert outpatient volume growth into the earnings profile many are assuming.Explore 2 other fair value estimates on Surgery Partners - why the stock might be worth just $25.73!Build Your Own Surgery Partners NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Surgery Partners research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.Contemplating Other Strategies?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589281938","isCrawlerRequest":true}